疫苗诱导的免疫性血小板减少症和血栓形成患者的长期结局
该前瞻性纵向研究纳入德国71例血清学确诊的疫苗诱导的免疫性血小板减少症和血栓形成(VITT)患者,自2021年3月至2023年1月随访平均79周,分析抗PF4抗体长期变化、复发血栓和/或血小板减少风险及再次接种疫苗的影响。
要点
- 71例VITT患者中62例(87.3%;95%CI 77.6%-93.2%)血小板激活型抗PF4抗体转为检测不到。
- 6例(8.5%)血小板激活型抗PF4抗体持续超过18个月。
- 5例(7.0%)出现复发性血小板减少和/或血栓,其中4例(80.0%)存在VITT以外的其他解释。
核心结论
- VITT急性期过后,患者复发血栓和/或血小板减少的风险似乎较低。
研究设计与样本
- 前瞻性纵向研究,纳入德国71例血清学确诊的VITT患者,自2021年3月至2023年1月随访平均79周。
主要发现
- 71例中62例(87.3%;95%CI 77.6%-93.2%)血小板激活型抗PF4抗体转为检测不到。
- 6例(8.5%)血小板激活型抗PF4抗体持续超过18个月。
- 5例(7.0%)出现复发性血小板减少和/或血栓,其中4例(80.0%)存在VITT以外的其他解释。
- 进一步接种信使RNA新冠疫苗后,未观察到血小板激活型抗PF4抗体再激活或新发血栓形成。
- 后续接种流感、蜱传脑炎、水痘、破伤风、白喉、百日咳和脊髓灰质炎疫苗的患者未发生不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rapid diagnosis and treatment has improved outcome of patients with vaccine-induced immune thrombocytopenia and thrombosis (VITT). However, after the acute episode, many questions on long-term management of VITT remained unanswered. OBJECTIVES: To analyze, in patients with VITT, the long-term course of anti-platelet factor 4 (PF4) antibodies; clinical outcomes, including risk of recurrent thrombosis and/or thrombocytopenia; and the effects of new vaccinations. METHODS: 71 patients with serologically confirmed VITT in Germany were enrolled into a prospective longitudinal study and followed for a mean of 79 weeks from March 2021 to January 2023. The course of anti-PF4 antibodies was analyzed by consecutive anti-PF4/heparin immunoglobulin G enzyme-linked immunosorbent assay and PF4-enhanced platelet activation assay. RESULTS: Platelet-activating anti-PF4 antibodies became undetectable in 62 of 71 patients (87.3%; 95% CI, 77.6%-93.2%). In 6 patients (8.5%), platelet-activating anti-PF4 antibodies persisted for >18 months. Five of 71 patients (7.0%) showed recurrent episodes of thrombocytopenia and/or thrombosis; in 4 of them (80.0%), alternative explanations beside VITT were present. After further COVID-19 vaccination with a messenger RNA vaccine, no reactivation of platelet-activating anti-PF4 antibodies or new thrombosis was observed. No adverse events occurred in our patients subsequently vaccinated against influenza, tick-borne encephalitis, varicella, tetanus, diphtheria, pertussis, and polio. No new thrombosis occurred in the 24 patients (33.8%) who developed symptomatic SARS-CoV-2 infection following recovery from acute VITT. CONCLUSION: Once the acute episode of VITT has passed, patients appear to be at low risk for recurrent thrombosis and/or thrombocytopenia.
引用
- Schönborn L, Seck SE, Thiele T, et al. Long-term outcome in vaccine-induced immune thrombocytopenia and thrombosis. J Thromb Haemost. 2023. PMID: 37394120. doi:10.1016/j.jtha.2023.06.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。